Management of Multiple Infections in an 83-Year-Old Hemodialysis Patient
For this elderly hemodialysis patient with Stenotrophomonas maltophilia in sputum, Candida in urine, liver dysfunction, coagulopathy, and elevated parathyroid hormone, trimethoprim-sulfamethoxazole should be initiated for the S. maltophilia infection, and fluconazole 200mg daily (adjusted for renal function) for the Candida infection, with careful monitoring of liver function and INR.
Stenotrophomonas maltophilia Management
- Trimethoprim-sulfamethoxazole (TMP-SMX) is the first-line treatment for S. maltophilia infections due to its good in vitro activity and favorable clinical outcomes 1
- For patients on hemodialysis, TMP-SMX dosing should be adjusted for renal function, typically administered after dialysis sessions 2
- Alternative options if TMP-SMX is contraindicated (given the patient's elevated liver enzymes and INR):
Candida Infection Management
- For Candida urinary tract infection in a hemodialysis patient, fluconazole is the recommended treatment 4
- Initial dosing: 200mg daily, with subsequent doses adjusted for hemodialysis 5
- For hemodialysis patients, fluconazole can be administered after dialysis sessions 4
- Treatment duration should be 14 days after clinical improvement 4
- Echinocandins (caspofungin, micafungin, or anidulafungin) are alternatives if fluconazole cannot be used due to liver dysfunction 4
Special Considerations for Hemodialysis Patients
Hemodialysis patients have unique challenges when managing infections 4:
- Limited vascular access
- Need for medication administration during dialysis sessions
- Altered pharmacokinetics requiring dose adjustments
- Higher risk of drug toxicity
Antibiotic dosing should be coordinated with dialysis schedule to ensure adequate drug levels 4
Addressing Liver Dysfunction and Coagulopathy
- The elevated INR (2.9) and liver enzymes indicate significant liver dysfunction that requires careful medication selection 4
- Monitor liver function tests and INR closely during antimicrobial therapy 4
- Consider reducing doses of hepatically metabolized medications 4
- Avoid medications with significant hepatotoxic potential when possible 4
- The coagulopathy (INR 2.9) requires careful monitoring, especially if invasive procedures are needed 4
Management of Secondary Hyperparathyroidism
- The elevated parathyroid hormone level (88.4) indicates secondary hyperparathyroidism, common in hemodialysis patients 4
- This condition should be addressed but is not the immediate priority given the active infections
- Standard management includes phosphate binders, vitamin D analogs, and calcimimetics 4
Monitoring and Follow-up
- Obtain follow-up cultures to ensure clearance of infections 4
- Monitor liver function tests, INR, and renal parameters regularly 4
- Assess for drug interactions between antimicrobials and the patient's regular medications 4
- Consider removal or exchange of any indwelling catheters if they are potential sources of infection 4
- Evaluate for potential sources of infection to prevent recurrence 4
Potential Pitfalls and Caveats
- S. maltophilia has intrinsic resistance to many antibiotics, making treatment challenging 1, 6
- Hemodialysis patients are at higher risk for drug toxicity and altered pharmacokinetics 4
- The combination of liver dysfunction and renal failure significantly limits medication options and requires careful dose adjustments 4
- Elderly patients (83 years old) may have altered drug metabolism and increased susceptibility to adverse effects 4
- Avoid nephrotoxic agents that could further damage residual kidney function 4